Good afternoon :)
Place Order
Add to Watchlist

Dr Reddy's Laboratories Ltd

DRREDDY Share Price

1,278.000.99% (+12.50)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹1,05,336 cr, stock is ranked 95

Stock is 1.52x as volatile as Nifty

DRREDDY Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹1,05,336 cr, stock is ranked 95

Stock is 1.52x as volatile as Nifty

DRREDDY Performance & Key Metrics

DRREDDY Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
18.543.100.63%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.896.280.77%

DRREDDY Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
48%
Analysts have suggested that investors can buy this stock

from 31 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

DRREDDY Company Profile

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.

Investor Presentation

View older View older 

Jul 23, 2025

PDF
View Older Presentations

DRREDDY Similar Stocks (Peers)

Compare with peers Compare with peers 

DRREDDY Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.15
37.15
1Y Return
4.48%
4.48%
Buy Reco %
84.85
84.85
PE Ratio
22.80
22.80
1Y Return
1.04%
1.04%
Buy Reco %
68.75
68.75
PE Ratio
62.33
62.33
1Y Return
11.89%
11.89%
Buy Reco %
75.00
75.00
PE Ratio
53.68
53.68
1Y Return
23.05%
23.05%
Buy Reco %
81.25
81.25
PE Ratio
21.60
21.60
1Y Return
17.65%
17.65%
Buy Reco %
42.86
42.86
Compare with Peers

DRREDDY Sentiment Analysis

DRREDDY Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

DRREDDY Stock Summary · January 2025

In Q3FY25, the company showcased robust revenue growth, largely fueled by the acquisition of the Nicotine Replacement Therapy business, despite facing challenges such as price erosion in the North American generics market and integration costs impacting profitability. While the European generics segment thrived, emerging markets, particularly India, demonstrated solid year-over-year growth, underscoring the company's commitment to innovation and strategic investments in R&D and new product launches. The proactive approach to biosimilars, alongside a focus on sustainability and operational excellence, positions the company favorably for future opportunities. However, regulatory hurdles and competitive pressures necessitate careful navigation to sustain momentum and profitability across diverse markets. Overall, a cautious optimism prevails as the company aligns its growth strategies with evolving market dynamics.

DRREDDY Stock Growth Drivers
DRREDDY Stock Growth Drivers
7
  • Strong Financial Performance

    In Q3FY25, the company achieved consolidated revenues of Rs. 8,359 crores ($977 million), reflecting a

  • Successful Integration of Acquisitions

    The company successfully consolidated the financials of the acquired NRT business in Q3FY25, contributing to

DRREDDY Stock Challenges
DRREDDY Stock Challenges
5
  • Decline in Financial Performance

    The company reported a decline in net finance income, dropping from Rs. 96 crores in

  • Slower Growth in Key Product Areas

    Certain brands within the Cardiac and Gastro-intestinal therapy areas experienced slower growth, with overall growth

DRREDDY Forecast

DRREDDY Forecasts

Price

Revenue

Earnings

DRREDDY

DRREDDY

Income

Balance Sheet

Cash Flow

DRREDDY Income Statement

DRREDDY Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.16%, vs industry avg of 10.15%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 7.25% to 8.06%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 22.79%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue14,367.6014,436.2015,829.5018,193.7019,386.9022,099.9025,762.2028,920.1033,762.9034,806.00
Raw Materialssubtract3,819.804,081.004,770.205,530.706,869.407,796.107,586.808,889.2010,524.6024,998.90
Power & Fuel Costsubtract330.10329.30329.10314.80320.50390.50477.40533.90562.50
Employee Costsubtract3,106.803,214.903,356.203,380.203,629.903,885.804,646.605,030.105,580.00
Selling & Administrative Expensessubtract3,287.102,106.102,235.302,184.202,398.302,976.103,199.303,710.204,736.30
Operating & Other expensessubtract1,180.102,198.501,579.203,636.701,959.502,729.002,410.601,914.602,693.40
Depreciation/Amortizationsubtract1,026.601,077.201,134.801,163.101,228.801,165.201,250.201,470.001,703.701,799.20
Interest & Other Itemssubtract63.4078.8088.9098.3097.0095.80142.80171.10282.90306.00
Taxes & Other Itemssubtract261.60403.60385.80-140.30931.90878.901,541.201,623.102,024.402,021.10
EPS15.3711.4223.5024.3923.4826.2454.1566.9367.7868.08
DPS4.004.004.005.005.006.008.008.008.008.00
Payout ratio0.260.350.170.200.210.230.150.120.120.12

DRREDDY Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

Jul 23PDF
Jul 23PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 9PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Jun 21PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

DRREDDY Stock Peers

DRREDDY Past Performance & Peer Comparison

DRREDDY Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dr Reddy's Laboratories Ltd18.633.100.63%
Sun Pharmaceutical Industries Ltd37.155.600.95%
Cipla Ltd22.803.841.08%
Torrent Pharmaceuticals Ltd62.3315.690.91%

DRREDDY Stock Price Comparison

Compare DRREDDY with any stock or ETF
Compare DRREDDY with any stock or ETF
DRREDDY
Loading...

DRREDDY Holdings

DRREDDY Shareholdings

DRREDDY Promoter Holdings Trend

DRREDDY Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

DRREDDY Institutional Holdings Trend

DRREDDY Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

DRREDDY Shareholding Pattern

DRREDDY Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding26.64%13.61%13.13%36.36%10.27%

Sep 2024

Dec 2024

Mar 2025

Jun 2025

DRREDDY Shareholding History

DRREDDY Shareholding History

MarJunSepDec '24MarJun44.49%42.27%41.75%40.08%37.29%36.36%

Mutual Funds Invested in DRREDDY

Mutual Funds Invested in DRREDDY

No mutual funds holding trends are available

Top 5 Mutual Funds holding Dr Reddy's Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.1854%1.20%-0.04%20/177 (-3)
1.1358%2.21%0.55%51/91 (0)
0.6100%1.47%-0.06%21/77 (-1)

Compare 3-month MF holding change on Screener

DRREDDY Insider Trades & Bulk Stock Deals

DRREDDY Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing DRREDDY stock

smallcases containing DRREDDY stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr Reddy's Laboratories Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

DRREDDY's Wtg.
12.20%
12.20%
CAGR
20.15%

DRREDDY Events

DRREDDY Events

DRREDDY Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DRREDDY has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.63%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.34 every year

Dividends

Corp. Actions

Announcements

Legal Orders

DRREDDY Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DRREDDY has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.63%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.34 every year

DRREDDY Upcoming Dividends

DRREDDY Upcoming Dividends

No upcoming dividends are available

DRREDDY Past Dividends

DRREDDY Past Dividends

Cash Dividend

Ex DateEx DateJul 10, 2025

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jul 10, 2025

Cash Dividend

Ex DateEx DateJul 16, 2024

Final
Final | Div/Share: ₹40.00

Dividend/Share

40.00

Ex DateEx Date

Jul 16, 2024

Cash Dividend

Ex DateEx DateJul 11, 2023

Final
Final | Div/Share: ₹40.00

Dividend/Share

40.00

Ex DateEx Date

Jul 11, 2023

Cash Dividend

Ex DateEx DateJul 11, 2022

Final
Final | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Jul 11, 2022

Cash Dividend

Ex DateEx DateJul 9, 2021

Final
Final | Div/Share: ₹25.00

Dividend/Share

25.00

Ex DateEx Date

Jul 9, 2021

DRREDDY Stock News & Opinions

DRREDDY Stock News & Opinions

Spotlight
Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr

Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY. In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY. Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase. Co-Chairman & MD, G V Prasad, said: We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
Dr Reddy's Lab receives EIR from USFDA for Middleburgh API facility

In a regulatory filing, the company stated that the EIR was issued following a good manufacturing practice (GMP) inspection conducted by the USFDA. The inspection outcome has been classified as Voluntary Action Indicated (VAI), and the inspection is now officially closed under 21 CFR 20.64(d)(3). This follows Dr. Reddy's earlier disclosure dated 17 May 2025, in which it informed that the USFDA had completed a GMP inspection of the Middleburgh facility. The inspection took place from 12 May to 16 May 2025 (US EST) and concluded with the issuance of a Form 483 containing two observations. The company confirmed that it will address the observations within the stipulated timeline. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's Laboratories reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip shed 0.44% to Rs 1,254 on the BSE. Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Dr Reddys Laboratories Ltd slips for fifth straight session

Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1267.7, down 0.71% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.38% on the day, quoting at 25444.25. The Sensex is at 83364.59, down 0.4%.Dr Reddys Laboratories Ltd has added around 1.55% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 3.31% in last one month and is currently quoting at 22041.25, up 0.09% on the day. The volume in the stock stood at 13.42 lakh shares today, compared to the daily average of 16.98 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1267.5, down 0.76% on the day. Dr Reddys Laboratories Ltd tumbled 1.36% in last one year as compared to a 4.77% rally in NIFTY and a 10.78% spurt in the Nifty Pharma index.The PE of the stock is 19.92 based on TTM earnings ending March 25.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Dr Reddys Laboratories to hold board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 23 July 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dr Reddys Laboratories allots 10,685 equity shares under ESOP

Dr Reddys Laboratories has allotted 10,685 equity shares under ESOPs on 23 June 2025. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dr Reddys Laboratories allots Equity shares

Dr Reddys Laboratories has allotted 57,885 equity shares of Re.1/- each of the Company, fully paid up, on June 14, 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy's Employees Stock Options Scheme, 2002 and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Dr Reddys Laboratories Ltd up for third consecutive session

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1364.9, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Dr Reddys Laboratories Ltd has gained around 13.07% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 11.71 lakh shares today, compared to the daily average of 17.74 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1361.1, up 0.71% on the day. Dr Reddys Laboratories Ltd is up 11.95% in last one year as compared to a 7.14% jump in NIFTY and a 12.03% jump in the Nifty Pharma index.The PE of the stock is 21.07 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Dr Reddys Laboratories Ltd soars 0.07%, up for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1321.8, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.46% on the day, quoting at 25117.25. The Sensex is at 82511.15, up 0.39%. Dr Reddys Laboratories Ltd has risen around 10.56% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 3.24% in last one month and is currently quoting at 21684.4, up 0.47% on the day. The volume in the stock stood at 9.1 lakh shares today, compared to the daily average of 19.37 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1320.2, up 0.24% on the day. Dr Reddys Laboratories Ltd is up 8.24% in last one year as compared to a 7.99% spurt in NIFTY and a 10.18% spurt in the Nifty Pharma index.The PE of the stock is 20.6 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $29.5 billion in 2024. The partnership involves joint development and manufacturing of the biosimilar, with both companies sharing costs and responsibilities. Subject to certain conditions, both parties will also have rights to commercialize the product worldwide. Alvotech, a biotech company focused on biosimilars, already has two approved biosimilars, adalimumab and ustekinumab, marketed in several countries. It has a strong pipeline of nine additional biosimilars and a global network of commercial partnerships spanning the US, Europe, Asia, Latin America, and Africa. Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. On a consolidated basis, net profit of Dr Reddy's Laboratories rose 21.64% to Rs 1593.30 crore while net sales rose 20.09% to Rs 8506 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that the companies have entered into a collaboration and license agreement to co develop, manufacture and commercialize a biosimilar candidate to Keytruda' (pembrolizumab) for global markets. Keytruda' (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Dr Reddy's Laboratories Ltd (DRREDDY) today?

    The share price of DRREDDY as on 25th July 2025 is ₹1278. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Dr Reddy's Laboratories Ltd (DRREDDY) share?

    The past returns of Dr Reddy's Laboratories Ltd (DRREDDY) share are
    • Past 1 week: -0.98%
    • Past 1 month: -5.54%
    • Past 3 months: 5.41%
    • Past 6 months: 3.36%
    • Past 1 year: -7.22%
    • Past 3 years: 44.68%
    • Past 5 years: 55.62%

  3. What are the peers or stocks similar to Dr Reddy's Laboratories Ltd (DRREDDY)?
  4. What is the dividend yield % of Dr Reddy's Laboratories Ltd (DRREDDY) share?

    The current dividend yield of Dr Reddy's Laboratories Ltd (DRREDDY) is 0.63.

  5. What is the market cap of Dr Reddy's Laboratories Ltd (DRREDDY) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Reddy's Laboratories Ltd (DRREDDY) is ₹105336.53 Cr as of 25th July 2025.

  6. What is the 52 week high and low of Dr Reddy's Laboratories Ltd (DRREDDY) share?

    The 52-week high of Dr Reddy's Laboratories Ltd (DRREDDY) is ₹1421.49 and the 52-week low is ₹1020.

  7. What is the PE and PB ratio of Dr Reddy's Laboratories Ltd (DRREDDY) stock?

    The P/E (price-to-earnings) ratio of Dr Reddy's Laboratories Ltd (DRREDDY) is 18.63. The P/B (price-to-book) ratio is 3.10.

  8. Which sector does Dr Reddy's Laboratories Ltd (DRREDDY) belong to?

    Dr Reddy's Laboratories Ltd (DRREDDY) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Dr Reddy's Laboratories Ltd (DRREDDY) shares?

    You can directly buy Dr Reddy's Laboratories Ltd (DRREDDY) shares on Tickertape. Simply sign up, connect your demat account and place your order.